Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

Breast Cancer Research and Treatment

Volumn 146, Issue 1, 2014, Pages 163-174

  Madhavan, Dharanija ^a,b   Wallwiener, Markus ^b   Bents, Karin ^b   Zucknick, Manuela ^a   Nees, Juliane ^b   Schott, Sarah ^b   Cuk, Katarina ^a,b   Riethdorf, Sabine ^c   Trumpp, Andreas ^a,d   Pantel, Klaus ^c   Sohn, Christof ^b   Schneeweiss, Andreas ^b   Surowy, Harald ^a,b   Burwinkel, Barbara ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Hi STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine GmbH   (Germany)

Author keywords

Breast cancer; Circulating DNA; Diagnostic marker; DNA integrity; Prognostic marker

Indexed keywords

DNA; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FREE SYSTEM; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA CONTENT; DNA DETERMINATION; DNA FRAGMENTATION; DNA INTEGRATION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; ALU SEQUENCE; APOPTOSIS; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; GENETICS; LONG INTERSPERSED REPEAT; METASTASIS; MORTALITY; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR CELL LINE;

ALU ELEMENTS; APOPTOSIS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; NEOPLASM METASTASIS; PROGNOSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903692972     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2946-2     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602 (Pubitemid 41081385)
3. Cardoso F, Castiglione M, Group EGW (2009) Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):15-18
4. Hanash SM, Baik CS, Kallioniemi O (2011) Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 8:142-150
5. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P (2000) Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 20:4751-4755
6. Pantel K, Alix-Panabiéres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16:398-406
7. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92:906-912 (Pubitemid 40462638)
8. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F et al (2011) Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol 50:700-710
9. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M et al (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18:5972-5982
10. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A et al (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132:1602-1612
11. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J et al (2013) Plasma MicroRNA panel for minimally invasive detection of breast cancer. PLoS One 8(10):e76729
12. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S et al (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270-4276 (Pubitemid 46630784)
13. Steinman CR (1975) Free DNA in serum and plasma from normal adults. J Clin Investig 56:512-515
14. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS et al (2013) Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10:377-389
15. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ et al (1997) K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112:1114-1120 (Pubitemid 27157521)
16. Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabrerizo MP et al (1998) Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:113-116 (Pubitemid 28125774)
17. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA et al (2013) Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med 51:1505-1510
18. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC et al (2003) Increased plasma DNA integrity in cancer patients. Cancer Res 63:3966-3968 (Pubitemid 36917913)
19. Jiang WW, Zahurak M, Goldenberg D, Milman Y, Park HL, Westra WH et al (2006) Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 119:2673-2676 (Pubitemid 44691324)
20. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ et al (2006) Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 52:1062-1069 (Pubitemid 43794418)
21. Hauser S, Zahalka T, Ellinger J, Fechner G, Heukamp LC, Vonr A et al (2010) Cell-free circulating DNA: diagnostic value in patients with renal cell cancer. Anticancer Res 30:2785-2789
22. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E et al (2008) Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 46:311-317 (Pubitemid 351317779)
23. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-1665 (Pubitemid 34292602)
24. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD (1998) Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17:89-97 (Pubitemid 28293013)
25. Wu TL, Zhang D, Chia JH, Tsao K, Sun CF, Wu JT (2002) Cellfree DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 321:77-87 (Pubitemid 34597056)
26. Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F et al (2011) High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6(9):e23418
27. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM (2007) Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35:W71-W74
28. Jurka J, Kapitonov VV, Pavlicek A, Klonowski P, Kohany O, Walichiewicz J (2005) Repbase Update, a database of eukaryotic repetitive elements. Cytogenet Genome Res 110:462-467 (Pubitemid 41159923)
29. Price AL, Eskin E, Pevzner PA (2004) Whole-genome analysis of Alu repeat elements reveals complex evolutionary history. Genome Res 14:2245-2252 (Pubitemid 39517330)
30. Diehl F, Schmidt K, Choti M, Romans K, Goodman S (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990
31. Markham NR, Zuker M (2005) DINAMelt web server for nucleic acid melting prediction. Nucleic Acids Res 33(Web Server issue):W577-W581
32. Team RDC (2010) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org.
33. Gerds TA, Schumacher M (2007) Efron-type measures of prediction error for survival analysis. Biometrics 63:1283-1287 (Pubitemid 350212588)
34. Umetani N, Hirmatsu S, Hoon DSB (2006) Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 1075(1):299-307 (Pubitemid 44532797)
35. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7(7):e41561
36. Cao G, Pei W, Lan J, Stetler RA, Luo Y, Nagayama T et al (2001) Caspase-activated DNase/DNA fragmentation factor 40 mediates apoptotic DNA fragmentation in transient cerebral ischemia and in neuronal cultures. J Neurosci 21(13):4678-4690 (Pubitemid 32565626)
37. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al (2011) Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17(7):860-866
38. Liu S, Edgerton SM, Moore D 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7(6):1716-1723 (Pubitemid 32708640)
39. Srinivas P, Abraham E, Ahamed I, Madhavan M, Vijayalakshmi NR, Nair MK et al (2002) Apoptotic index: use in predicting recurrence in breast cancer patients. J Exp Clin Cancer Res 21(2):233-238 (Pubitemid 34785561)
40. Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber P (2008) DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci 1137:162-170
41. Ellinger J, Muller SC, Wernert N, von Ruecker A, Bastian PJ (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102:628-632
42. Hauser S, Kogej M, Fechner G, Von Ruecker A, Bastian PJ, Von Pezold J et al (2012) Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res 32:3119-3124
43. El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222-230